Zidine-300 Tablets

Indications And Usage of Zidine-300 Tablets:
Treatment of HIV infection
Prevention of maternal-fetal HIV transmission

Contraindications
Patients with hypersensitivity to any of the components of the formulation

Warnings
Zidovudine should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count <1000 cells/mm3 or hemoglobin <9.5 g/dL. There have been reports of pancytopenia associated with the use of zidovudine. Myopathy and myositis with pathological changes, similar to that produced by HIV disease, have been associated with prolonged use of zidovudine. Rare occurrences of potentially fatal lactic acidosis in the absence of hypoxemia, and severe hepatomegaly with steatosis have been reported. Caution should be exercised when administering zidovudine to any patient, particularly obese women, with hepatomegaly, hepatitis, or other known risk factor for liver disease.

Precautions
Patients with severely impaired hepatic function may be at greater risk of toxicity. No data is available on its teratogenic potential in humans. Zidovudine is excreted in human milk. HIV-infected women should not breastfeed to avoid postnatal transmission of HIV to a child who may not yet be infected.